Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases

    Category: TG4010

    Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

    20151223_TIME Ph2b Lancet Oncology 2015_PR EN

    Published 23 December 2015
    Categorized as 2015, Press release, TG4010

    TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

    Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication

    Published 18 December 2015
    Categorized as 2015, Publication, TG4010

    TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial

    John Nemunaitis, et al. SITC 2015, November 2015 – Abstract available on the SITC website Download the poster here Poster Presentation

    Published 13 November 2015
    Categorized as 2015, Publication, TG4010

    TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.

    Elisabeth Quoix, et al. 16th World Conference on Lung Cancer. September 2015, Denver, Colorado Download the poster here Poster Presentation

    Published 10 September 2015
    Categorized as 2015, Publication, TG4010

    Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

    20150908 PR TG4010 IASLC revised – BIS

    Published 8 September 2015
    Categorized as 2015, Press release, TG4010

    Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

    19 August 2015_PR_IASLC curtain raiser_ENG

    Published 19 August 2015
    Categorized as 2015, Press release, TG4010

    Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)

    20150601 PR TG4010 TIME results_ASCO 2015_FINAL

    Published 1 June 2015
    Categorized as 2015, Press release, TG4010

    Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy

    Elisabeth Quoix, et al. ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois Download the poster here Poster Presentation

    Published 1 June 2015
    Categorized as 2015, Publication, TG4010

    Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody

    20150421 AACR 2015_English

    Published 21 April 2015
    Categorized as 2015, Press release, TG3003, TG4010

    Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer

    Poster TG4010-AACR 2015-KR Karola Rittner, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497 Download the posterhere Poster Presentation

    Published 21 April 2015
    Categorized as 2015, Publication, TG4010

    Posts navigation

    Newer posts Page 1 Page 2 Page 3 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo